BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of BrightGene Bio-Medical Technology Co (688166.SS) as of Oct 23, 2026 is 1.24 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 4.86 % — a change of -74.47% (lower).

EBIT/Assets

1.24 %

YoY

-74.47%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of BrightGene Bio-Medical Technology Co is 2025 1.24 % . Operating Income to Assets Ratio (EBIT/Assets) of BrightGene Bio-Medical Technology Co was 2024 4.86 % . It decreases by -74.47% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
9.88 CNY
Jan 1, 2019
8.84 CNY
Jan 1, 2020
11.39 CNY
Jan 1, 2021
9.24 CNY
Jan 1, 2022
5.68 CNY
Jan 1, 2023
5.04 CNY
Jan 1, 2024
4.86 CNY
Jan 1, 2025
1.24 CNY
The BrightGene Bio-Medical Technology Co EBIT/Assets history
YEAREBIT/AssetsYoY
1.24 %-74.47%
4.86 %-3.63%
5.04 %-11.23%
5.68 %-38.55%
9.24 %-18.90%
11.39 %+28.87%
8.84 %-10.52%
9.88 %-8.28%
10.77 %+121.56%
4.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Operating Income to Assets Ratio (EBIT/Assets) of BrightGene Bio-Medical Technology Co is 1.24 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of BrightGene Bio-Medical Technology Co changed from 4.86 % to 1.24 %, representing a -74.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — BrightGene Bio-Medical Technology Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — BrightGene Bio-Medical Technology Co